CReATe Podcast CReATe Consortium
-
- Health & Fitness
-
CReATe Connect podcasts are short recorded interviews on topics we hope will be of interest to patients with ALS and other motor neuron diseases.
-
CReATe Author Series Ep. 10 - Drs. McHutchison and Benatar on Cognitive and Behavioral Changes in MND
Dr. Caroline McHutchison is a Neuropsychologist and CReATe Clinical Research Scholar at the University of Edinburgh and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication “Temporal course of cognitive and behavioural changes in motor neuron diseases”.
-
CReATe Author Series Ep. 9 - Drs. Heatwole and Benatar on Patient Reported Outcome Measures and ALS
Dr. Chad Heatwole is a Professor of Neurology and the Director of the Center for Health and Technology at the University of Rochester Medical Center and Dr. Michael Benatar is a Professor of Neurology and Chief of the Neuromuscular Division and Executive Director of the ALS Center at the University of Miami. They will be discussing their recent publication “The amyotrophic lateral sclerosis-health index (ALS-HI): development and evaluation of a novel outcome measure” and its role as a patient reported outcome measure for ALS.
-
ALS Untangled Series Ep. 56 - Sodium Chlorite
Sodium chlorite is an experimental drug targeting macrophage activation. It exists in different formulations. An oral formulation has potentially deadly side effects. An IV formulation called NP001 has been in recent trials targeting a subset of people with ALS. Here we review the interesting development of this product and where we expect that to go in the near future.
-
ALS Untangled Series Ep. 55 - Rituximab
Rituximab is an intravenous product that reduces B lymphocytes. It can help improve strength in patients with myasthenia gravis and multi-focal motor neuropathy, neuromuscular diseases that are caused by circulating antibodies made by B lymphocytes. In this podcast we examine the possible use of rituximab to treat patients with ALS
-
ALS Untangled Series Ep. 54 - Ozone Therapy
Ozone is an oxidizing agent which has some surprisingly plausible mechanisms by which it could influence ALS progression. It can also be dangerous. The FDA has warned against using it as a treatment for any disease. Further studies are needed to determine whether there is any dose or route of administration that might be safe and effective for use in people with ALS.
-
ALS Untangled Series Ep. 53 - Astaxanthin
Astaxanthin is a naturally occurring chemical which has plausible mechanisms for treating ALS and appears reasonably safe and well tolerated in non-ALS trials. We look forward to ALS-specific trials planned later this year which should shed important light on whether this is specifically safe for people with ALS, and whether it really can slow ALS progression.
Customer Reviews
So helpful!
This podcast is so helpful for pALS and caregivers pursuing alternative treatments. I did my doctoral work in genetics, but have no experience in human biology, much less neurobiology, and consequently found myself overwhelmed when researching treatments for a loved one. This podcast does such a great job describing the disease pathology and the mechanisms through which particular treatments might work. The way they structure their analysis of potential therapies makes it easy to compare them and focus on those those that seem most promising. Thank you so much for taking the time to put this together!